Previous 10 | Next 10 |
home / stock / esaly / esaly news
The US FDA on Friday granted accelerated approval to Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) Leqembi (lecanemab), just the second biologic medicine ever approved for Alzheimer's disease. The therapy is expected to become available around the week of Jan. 23. It com...
Eisai's Commitment to Scientific Evidence and Patient Safety PR Newswire Hope for Patients with Early Alzheimer's Disease TOKYO , Jan. 6, 2023 /PRNewswire/ -- LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people livin...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One stock that’s trading in the right direction today is prominent mega-cap biotech stock Biogen (NASDAQ: BIIB ). Shares of BIIB stock have surged around 3.7% as of early afternoon trading on apparent hopes...
Biogen ( NASDAQ: BIIB ) is separating its research and development department into two separate units , a day before the US FDA is set to act on its application for Alzheimer's therapy lecanemab. Priya Singhal, currently Head of Global Safety and Regulatory Sciences and interim He...
Summary Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths. The FDA may still grant approval to lecanemab with a warning label regarding brain bleeds and brain swelling. Medica...
Summary Today, we put Acumen Pharmaceuticals in the spotlight for the first time. The stock of this Alzheimer's focused developmental concern is trading near its net cash on the balance sheet. An investment analysis follows in the paragraphs below. For further ...
EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA PR Newswire TOKYO and CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarte...
Astellas Pharma ( OTCPK:ALPMF ), Eisai ( OTCPK:ESALY ), Daiichi Sankyo ( OTCPK:DSKYF ), and Takeda Pharmaceutical ( OTCPK:TKPHF ) have agreed the collaboration to reduce environmental burden in the field of pharmaceutical packaging. Per the terms, the four firms will aim t...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...
Catalyst Pharmaceuticals ( NASDAQ: CPRX ) will acquire the U.S. rights to Eisai's ( OTCPK:ESALY ) epilepsy drug Fycompa (perampanel) as well as a period to review and negotiate the acquisition of a rare epilepsy asset in the Japanese drugmaker's pipeline. Terms calls for Eisai (...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...